Somatostatin and its receptors in ovarian tumors
Author Information
Author(s): Hall G H, Turnbull L W, Richmond I, Helboe L, Atkin S L
Primary Institution: University of Hull
Hypothesis
The study aims to explore the expression of somatostatin and its receptors in benign and malignant ovarian tumors.
Conclusion
The study found that both benign and malignant ovarian tumors express high levels of somatostatin and its receptors, suggesting potential therapeutic implications.
Supporting Evidence
- 90% of malignant tumors expressed somatostatin.
- 74% of benign tumors expressed somatostatin.
- Significant correlation between somatostatin and its receptors in malignant tumors.
Takeaway
This study looked at how a substance called somatostatin and its receptors are found in both healthy and unhealthy ovarian tumors, which might help in treating ovarian cancer.
Methodology
The study used immunohistochemistry to analyze somatostatin and its receptor expression in 63 malignant and 35 benign ovarian tumors.
Participant Demographics
Mean age of patients was 57 years for benign and 59 years for malignant tumors, with a range from 26 to 85 years.
Statistical Information
P-Value
P=0.008, P<0.001, P=0.019, P=0.026, P=0.034, P=0.044, P=0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website